iMenu
Affiliations
Partnership

Author : Admin
Article ID : 68
Audience : Default
Version 1.00.16
Published Date: 2010/4/29 22:48:37
Reads : 2111

Northeastern Section of American Chemical Society (NESACS) and Chinese -American BioMedical Association (CABA) are organizing a scientific symposium on Saturday, May 22 at Holiday Inn of Woburn, MA (15 Middlesex Canal Park Road). This symposium will feature "Drug R&D in China: Status, Opportunity, International Collaboration and Challenges". Comparing to the well-established Chinese Pharmaceutical CRO services sector, China's innovative drug R&D has shown its momentum only in recent several years. Prominent academic professors and seasoned industrial scientists and executives from both China and US will share their views on China's drug R&D and the impact to the global pharmaceutical industry. Don't miss this unique opportunity to learn about China's drug R&D status and to network with leaders in this field.

NESACS and CABA members will enjoy a discount rate ($30 for ACS members, $20 for CABA members, $35 for non-members) to attend this symposium.

Pre-registration is required. Please register before May 19 by accepting the Evite invitation below. Please put down your full name and affiliation so that a proper nametag can be prepared for you by the organizers beforehand.
http://www.evite.com/app/publicUrl/SIEVVUIRCDIGGZEPGSVP/ChinaRnD

Attached is the flyer. For more information and updates, please go to www.NESACS.org.

DRUG R&D IN CHINA - Status, Opportunity, International Collaboration and Challenges

Organizer by
Northeastern Section of American Chemical Society (NESACS)
Chinese-American BioMedical Association (CABA)

Saturday, May 22nd, 2010
Holiday Inn (15 Middlesex Canal Park Road, Woburn, MA)

Program

8:30~9:00 Registration

9:00~9:05 Welcome
Dr. Liming Shao (Chair of Medicinal Chemistry, NESACS)

9:05~9:15 Opening Remarks
Dr. John Neumeyer (Harvard Medical School, McLean Hospital)

9:15~12:00 Session I
Drug discovery in China and Chinese pharmaceutical industry - Status and opportunity, Chair, Dr. Yuan Wang (Director, Discovery, Oncology-PCU, Eisai)

9:20~10:00 Drug Discovery in China - An Insider’s View
Dr. Jingkang Shen (Professor, Shanghai Institute of Materia Medica, Chinese Academy of Science)

10:00~10:30 Trends of World Drug R&D - A Global View of Chinese Pharmaceutical Industry, Christopher-Paul Milne, DVM, MPH, JD (Associate Director, Center for the Study of Drug Development, Tufts University)

10:30~10:45 Break

10:45~11:15 New drug discovery: starting from the old ones, Dr. Hongbing Sun (Professor of Medicinal Chemistry, Director of Center of Drug Discover, China Pharmaceutical University)

11:15~11:45 Build up discovery capability, a story from a small biotech company, Dr. Michael Song (COO/CSO, KBP Bioscience, China)

11:45~1:00 Lunch

Session II
1:00-3:00 Leveraging China’s drug discovery through international collaboration, Chair, Dr. Zhijian Lu (Director, Extramural Partnered Research, Asia, Global Biotherapeutics Technologies, Pfizer)

1:00~1:30pm Building a library of authenticated, quality controlled, source-documented Traditional Chinese Medicine (TCM) plants at Harvard Medical School: an international collaboration to identify new therapeutic opportunities, Dr. Bruce Littlefield (Harvard University, Medical School)

1:30~2:00pm Current Status and Future Directions of Simcere’s Pharmaceutical R&D, Dr. Peng Wang (CSO, Simcere Pharmaceutical Group)

2:00~2:30pm Partnering for Success: An Overview of Pfizer’s R&D Innovation Efforts in China, Dr. Yuan-Hua Ding (Director, Head of External R&D Innovation – Asia, Pfizer Biotherapeutics Research and Development)

2:30~3:00pm Establishment of a world-leading Oncology R&D innovation group in Shanghai: the AstraZeneca experience, Dr. Luciene Ronco (Global Director of Discovery Medicine and Translational Science, AstraZeneca)

3:00~3:30 Panel Discussion, Moderator, Dr. Chaoyang Dai, (President, CABA)

3:30~4:00 Break

4:00~6:00 Session III
Challenges and opportunities Drug R&D in China. Chair, Dr. Yibin Xiang (Sr. Director, Medicinal Chemistry, Genzyme)

4:00~4:30 It is all possible - from Tianyuan’s success story to look at opportunity in drug R&D in China, Dr. Sam Liao (Head of Business Development & Licensing, Novartis Vaccines & Diagnostics)

4:30~5:00 Development of Multi-Targeted siRNA Therapeutics with Nanoparticle-Enhanced Delivery Systems, Patrick Y. Lu, Ph.D. (Founder, President and CEO of Sirnaomics, Inc)

5:00~5:30 Is IP still an issue for drug R&D in China? - Recent changes and progress for IP protection in China, Philip Zhang, Ph.D. (Esq. Co-Founder of Principal Milstein Zhang & Wu LLC)

5:30~6:00 To pursue IP protection in China - understanding the commons and differences of IP protection between US and China through case studies, Michael McGurk, Partner (Finnegan)

6:00~7:00 Social Hour Reception (Sponsored by Sundia MediTech Company)


0
Printer Friendly Page Send this Article to a Friend
Copyright © 2014, CABA. All Rights Reserved.
Login
Username:

Password:


Lost Password?

Register now!
Mailing Address
CABA
P. O. Box 600241
Newtonville, MA 02460

CABA Connect
Sponsors

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window

Open in new window






Copyright © 2007 CABA